Production (Stage)
Pacific Biosciences of California, Inc.
PACB
$1.14
$0.1414.00%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 152.36M | 154.01M | 173.15M | 188.87M | 200.43M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 152.36M | 154.01M | 173.15M | 188.87M | 200.43M |
Cost of Revenue | 110.07M | 106.14M | 118.71M | 129.56M | 139.55M |
Gross Profit | 42.29M | 47.87M | 54.43M | 59.32M | 60.88M |
SG&A Expenses | 171.43M | 175.02M | 164.97M | 171.56M | 173.75M |
Depreciation & Amortization | 386.94M | 27.40M | 27.40M | 21.47M | 14.81M |
Other Operating Expenses | 5.07M | 998.00K | 3.44M | 3.44M | 3.44M |
Total Operating Expenses | 794.02M | 444.48M | 460.62M | 494.12M | 513.23M |
Operating Income | -641.67M | -290.46M | -287.47M | -305.25M | -312.80M |
Income Before Tax | -657.73M | -309.54M | -394.96M | -411.81M | -308.32M |
Income Tax Expenses | 14.00K | 316.00K | -718.00K | -11.42M | -11.42M |
Earnings from Continuing Operations | -657.75 | -309.85 | -394.24 | -400.38 | -296.90 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -657.75M | -309.85M | -394.24M | -400.38M | -296.90M |
EBIT | -641.67M | -290.46M | -287.47M | -305.25M | -312.80M |
EBITDA | -239.05M | -249.28M | -246.15M | -271.13M | -285.97M |
EPS Basic | -2.29 | -1.14 | -1.46 | -1.50 | -1.14 |
Normalized Basic EPS | -1.37 | -0.65 | -0.65 | -0.70 | -0.72 |
EPS Diluted | -2.29 | -1.14 | -1.46 | -1.50 | -1.14 |
Normalized Diluted EPS | -1.35 | -0.64 | -0.65 | -0.70 | -0.72 |
Average Basic Shares Outstanding | 1.13B | 1.10B | 1.08B | 1.06B | 1.04B |
Average Diluted Shares Outstanding | 1.15B | 1.12B | 1.08B | 1.06B | 1.04B |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |